Is Avacta Group Plc (AVCTF) a Buy, Sell, or Hold?
OTC : AVCTF
Avacta Group Plc
$0.9064 USD
$0 (0.0%)
- Volume
- 12K
- Average Volume
- 10.38K
- Market Capitalization
- $424.56M
- P/E Ratio
- -7.41
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $1.23
- Year Low
- $0.53
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.89
Company Overview
OTC
Christina Marie Coughlin
Biotechnology
Healthcare
AVCTF
154
GB
USD
Liquidity Metrics
6.02
0.89
0.89
0.64
0.00
Sales & Valuation
$112.98K
2861.55
121.75
-13.04
-0.06
Profitability
-$0.0965
-$38.37M
-33961.06%
-32604.42%
-2929.47%
-130.46%
P/E Metrics
-7.41
0.07
0.07
Analyst Price Target & Rating
1/5
1 Analysts
%
Financial Health Scores
-7.48
3/9
-$2.96M
$29.41M
$26.94M
-$61.1M
Key Metrics (TTM)
$316.58M
2801.56
-11.06
0.89
-2929.47%
-171.00%
-12.92%
-7.79%
17925 days
Company Executives
| Name | Title |
|---|---|
| David Wilson | Chief Commercial Officer of Diagnostics |
| Karen Harrison | Chief Operating Officer |
| Francis Wilson | Chief Scientific Officer |
| Christina Coughlin | Chief Executive Officer & Executive Director |
| David Liebowitz | Chief Medical Officer |
| Emma Wright | Group In-House Counsel |
| Brian Hahn | Chief Financial Officer & Company Secretary |
| Michael Vinegrad | Group Communications Director |
| R. Craig Slater | Chief Operating Officer of Diagnostics |
| Sebastien Goenen | Chief Operating Officer of Coris BioConcept |
| Anne McGurk | Joint Managing Director of Launch Diagnostics |
Poll Results
No votes yet today — be the first to share your view!
About Avacta Group Plc (OTC:AVCTF) Stock
Avacta Group Plc, a biopharmaceutical enterprise operating at the clinical stage, was established in 2003 and is headquartered in Wetherby, UK. The company specializes in the creation of cancer treatments and diagnostic solutions, leveraging its distinctive Affimer and pre|CISION proprietary platforms. Its operations span the United Kingdom, North America, South Korea, and broader regions of Asia and Europe, structured into two main divisions: Diagnostics and Therapeutics. The Diagnostics division is responsible for developing customized Affimer proteins for both external clients and its own diagnostic assays. This segment also manufactures the AffiDX SARS-CoV-2 rapid antigen lateral flow tests and supplies Affimer reagents for integration into other companies' products. Concurrently, the ... Therapeutics division focuses on advancing innovative cancer immunotherapies, strategically combining Avacta's proprietary technologies. Avacta has forged a variety of key partnerships and collaborations. These include a research alliance concerning its pre|CISION technology, which utilizes a substrate engineered for cleavage by fibroblast activation protein alpha; a drug development collaboration with LG Chem Life Sciences; a joint venture with Tufts University School of Medicine to progress Affimer drug conjugate therapies; a licensing deal with POINT Biopharma Inc. for the development of tumour-activated radiopharmaceuticals; and a drug development alliance with AffyXell to engineer mesenchymal stem cells for the treatment of autoimmune diseases.
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
2026-07-08 02:00:00
LONDON and PHILADELPHIA, July 08, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce the appointment of Dr. Patrick Vink, a seasoned healthcare executive, to its Board of Directors as Non-Executive Deputy Chairman and Senior Independent Director. Dr. Vink serves as Chairman at Arch Biopartners Inc (TSXV:ARCH, OTCQB:ACHFF) and on the board of Spero Therapeutics Inc. (NASDAQ:SPRO) as Nominating and Corporate Governance Chair.
2026-06-01 02:00:00
Multiple confirmed partial and minor responses observed in patients with SGC Continuing very good safety profile, with removal of the lifetime maximum doxorubicin limit based on highly favorable cardiac safety LONDON and PHILADELPHIA, June 01, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today released updated Phase 1a/1b and pharmacokinetics (PK), safety, toxicity and preliminary efficacy data with faridoxorubicin (AVA6000, pre|CISION®-enabled doxorubicin) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Christina Coughlin, CEO of Avacta, commented: "Today's data further underscores our confidence in both our Gen One product faridoxorubicin (AVA6000) and our pre|CISION ® technology to significantly improve treatment options for cancer patients.
Avacta Group Plc (AVCTF) Q4 2025 Earnings Call Transcript
2026-05-25 16:47:05
Avacta Group Plc (AVCTF) Q4 2025 Earnings Call Transcript
Unaudited Preliminary Results for the Year Ended December 31, 2025
2026-05-19 02:14:00
LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited preliminary results for the 12 months ended December 31, 2025 ("FY25").
2026-05-06 02:00:00
LONDON and PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, will today present two new developments at its Science Day 2026 event.
Frequently Asked Questions
-
What is the current Avacta Group Plc (AVCTF) stock price?
-
Avacta Group Plc(OTC:AVCTF) stock price is $0.9064 in the last trading session. During the trading session, AVCTF stock reached the peak price of $1.23 while $0.5286 was the lowest point it dropped to. The percentage change in AVCTF stock occurred in the recent session was 0.0% while the dollar amount for the price change in AVCTF stock was $0.
-
AVCTF's industry and sector of operation?
-
The OTC listed AVCTF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AVCTF?
-
David Wilson | Chief Commercial Officer of Diagnostics
Karen Harrison | Chief Operating Officer
Francis Wilson | Chief Scientific Officer
Christina Coughlin | Chief Executive Officer & Executive Director
David Liebowitz | Chief Medical Officer -
How many employees does AVCTF have?
-
Number of AVCTF employees currently stands at 154. AVCTF operates from Scale Space White City Imperial College Campus, London, GL W12 7RZ, GB.
-
Link for AVCTF official website?
-
Official Website of AVCTF is: https://www.avacta.com
-
How do I contact AVCTF?
-
AVCTF could be contacted at phone #44 1904 217 070 and can also be accessed through its website. AVCTF operates from Scale Space White City Imperial College Campus, London, GL W12 7RZ, GB.
-
How many shares of AVCTF are traded daily?
-
The average number of AVCTF shares traded daily for last 3 months was 10.38K.
-
What is the market cap of AVCTF currently?
-
The market value of AVCTF currently stands at $424.56M with its latest stock price at $0.9064